ArticleNucleic acids research2025
Structural basis for ligand recognition in the tobramycin riboswitch.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recently, a novel tobramycin-responsive riboswitch was developed by a combination of Capture-SELEX and in vivo screening. This riboswitch regulates translation initiation in eukaryotes with a high dynamic range and remarkable ligand affinity and selectivity. Its secondary structure differs from all previously described aminoglycoside-binding RNA motifs, suggesting a novel mode of ligand recognition. To provide a structural basis for the remarkable regulatory efficiency and ligand selectivity of this riboswitch, we investigated its structure in complex with its cognate ligand tobramycin by high-resolution solution nuclear magnetic resonance spectroscopy. The structure of the complex reveals a novel structural organization for an aminoglycoside binding motif with a unique pattern of intermolecular hydrogen bonds and electrostatic interactions between the RNA and functional groups of all three rings of the ligand. In contrast to other aminoglycoside binding motifs, ligand binding of the tobramycin riboswitch is coupled with the formation of an extensive network of noncanonical RNA-RNA interactions, rationalizing the high ligand affinity of this small hairpin RNA. Comparison with the free form of the RNA shows that the latter is much less compact, lacking many RNA-RNA interactions, in particular in the bulge regions, thereby immediately providing a rationale for the exceptional switching efficiency of this synthetic riboswitch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.